PMID- 35959915
OWN - NLM
STAT- MEDLINE
DCOM- 20220815
LR  - 20220817
IS  - 2165-5987 (Electronic)
IS  - 2165-5979 (Print)
IS  - 2165-5979 (Linking)
VI  - 13
IP  - 6
DP  - 2022 Jun
TI  - Efficacy and safety of mycophenolate mofetil in the treatment of moderate to 
      severe Graves' orbitopathy: a meta-analysis.
PG  - 14719-14729
LID - 10.1080/21655979.2022.2101191 [doi]
AB  - The role of mycophenolate mofetil (MMF) in the treatment of Graves' orbitopathy 
      (GO) has attracted much attention. This study is to evaluate the benefit and 
      safety of MMF in moderate-to-severe GO. A meta-analysis of clinical control 
      trials comparing MMF (with or without glucocorticoid (GC)) for the treatment of 
      GO with GC was conducted. We searched the databases, including PubMed, EMBASE, 
      the Cochrane Library, Web of Science, Wanfang, and China National Knowledge 
      Infrastructure (CNKI), for articles published up to 15 June 2022. The primary 
      outcome is referred to the improvement in overall response, and secondary 
      outcomes included the change in clinical activity score (CAS) and adverse events 
      (AEs). Of the 289 articles initially searched, 6 studies were finally eligible 
      for inclusion. The results showed that MMF (with or without GC) was superior to 
      GC in the treatment of GO (OR 3.34, 95% CI 2.17-5.14; p < 0.00001). Subgroup 
      analyses also showed that MMF monotherapy was more effective than GC (OR 4.46, 
      95% CI 2.52-7.87; p < 0.00001). Compared to methylprednisolone (MP) monotherapy, 
      a combination of MP and MMF was more effective. CAS decreased even more 
      significantly (WMD 0.29, 95% CI 0.10-0.48; p = 0.002) and fewer AEs occurred (OR 
      0.2, 95% CI 0.06-0.72; p = 0.01) in patients receiving MMF. The pooled data 
      suggested that MMF treatment in GO might be promising. Compared with GC therapy, 
      MMF is safer and more effective. However, more large-sample and high-quality 
      studies targeting MMF use in GO patients and long-term surveillance of prognosis 
      are urgently needed.
FAU - Feng, Wenwen
AU  - Feng W
AD  - Department of Endocrinology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Hu, Yifang
AU  - Hu Y
AD  - Department of Endocrinology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
AD  - Department of Geriatric Endocrinology, the First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, China.
FAU - Zhang, Chengzhou
AU  - Zhang C
AD  - Department of Endocrinology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
AD  - Department of Internal Medicine, Maternal and Child Health Hospital of Yancheng, 
      Yancheng, China.
FAU - Shi, He
AU  - Shi H
AD  - Department of Nuclear Medicine, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - Department of Ophthalmology, Ili & Jiangsu Joint Institute of Health, the 
      Friendship Hospital of Ili Kazakh Autonomous Prefecture, Ili, China.
FAU - Yang, Yanli
AU  - Yang Y
AD  - Department of Endocrinology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Chen, Shiying
AU  - Chen S
AD  - Department of Endocrinology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
FAU - Cui, Weijiang
AU  - Cui W
AD  - Department of Ophthalmology, Ili & Jiangsu Joint Institute of Health, the 
      Friendship Hospital of Ili Kazakh Autonomous Prefecture, Ili, China.
FAU - Cui, Dai
AU  - Cui D
AUID- ORCID: 0000-0001-5534-9558
AD  - Department of Endocrinology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Bioengineered
JT  - Bioengineered
JID - 101581063
RN  - HU9DX48N0T (Mycophenolic Acid)
SB  - IM
MH  - China
MH  - *Graves Ophthalmopathy/chemically induced/drug therapy
MH  - Humans
MH  - *Mycophenolic Acid/adverse effects
MH  - Treatment Outcome
PMC - PMC9377259
OTO - NOTNLM
OT  - Graves' orbitopathy
OT  - Mycophenolate mofetil
OT  - meta-analysis
OT  - treatment
COIS- No potential conflict of interest was reported by the authors.
EDAT- 2022/08/13 06:00
MHDA- 2022/08/16 06:00
PMCR- 2022/08/12
CRDT- 2022/08/12 08:03
PHST- 2022/08/12 08:03 [entrez]
PHST- 2022/08/13 06:00 [pubmed]
PHST- 2022/08/16 06:00 [medline]
PHST- 2022/08/12 00:00 [pmc-release]
AID - 2101191 [pii]
AID - 10.1080/21655979.2022.2101191 [doi]
PST - ppublish
SO  - Bioengineered. 2022 Jun;13(6):14719-14729. doi: 10.1080/21655979.2022.2101191.